Pentoxifylline Therapy in Biliary Atresia

• Status: Recruiting
• Trial end date: 2022-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether pentoxifylline reduces liver damage in infants with biliary atresia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Baylor College of Medicine
• Collaborator: Texas Children's Hospital
• Treatments: Bilirubin; Pentoxifylline

Criteria

Inclusion Criteria:

• 0-180 days old

• Diagnosed with biliary atresia through liver biopsy and/or intra-operative cholangiogram

• No previous Kasai portoenterostomy performed at another institution

• Able to take medications orally

• Legal guardian signs consent after understanding risks and investigational nature of study

Exclusion Criteria:

• Infants greater than 180 days old

• Infants receiving a Kasai portoenterostomy at another institution

• Infants unable to take medications orally